Agilent announces expansion of life sciences business

LCGC Europe eNews

LCGC Europe eNews-12-09-2011, Volume 0, Issue 0

Agilent has announced the expansion of its life sciences business with two important acquisitions: Halo Genomics and BioSystem Development.

Agilent has announced the expansion of its life sciences business with two important acquisitions: Halo Genomics and BioSystem Development.

Based in Uppsala, Sweden, Halo Genomics are a provider of innovative technology that addresses sequence-selective sample preparation in next-generation DNA sequencing. The company’s HaloPlex technology helps to remove bottlenecks associated with targeted resequencing without having to use expensive instruments or arduous protocols.

Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division, commented, “Halo Genomics’ unique technology and talented R&D team will expand Agilent’s solutions for emerging sequencing applications and accelerate our entry into the rapidly growing next-gen clinical sequencing market.”

“With Halo’s innovative technology and Agilent’s market-leading products and long history of quality and service, we look forward to offering our customers an expanded portfolio of solutions to meet their needs,” said Olle Ericsson, former CEO and founder of Halo Genomics.

BioSystem Development creates and manufactures solutions to meet the analytical needs of the life sciences industry. They currently supply Agilent’s Automation Solutions with AssayMap cartridges that are used in conjunction with Agilent’s Bravo liquid-handling platform for protein purification and characterization workflows. Together they enable true chromatographic separation with precision flow control, reducing drug discovery and development time and increasing lab efficiency.

“BioSystem Development’s innovative and versatile microchromatography technology, and the team’s applications expertise, will help Agilent expand its capabilities as a sample-prep provider for the life sciences market,” said Fred Strohmeier, vice president and general manager of Agilent’s Liquid Phase Analysis Division.

Scott Fulton, CEO of BioSystem Development, commented, “As an industry leader in providing innovative automation solutions, we are very excited to join the Agilent family.”

For more information, please visit ref="http://www.agilent.com">www.agilent.com